Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need.

Our Mission:

Working together to deliver gene and cell therapies for people impacted by serious diseases. Our strategy to harness the promise of genetic medicine to transform the lives of patients is inspired by our vision, to realize a world where cure is the new standard of care.

Gene therapy is the use of DNA as a potential therapy to treat a disease. In many disorders, particularly genetic diseases caused by a single genetic defect, gene therapy aims to treat a disease by delivering the correct copy of DNA into a patient's cells. The functional copy of the therapeutic gene then helps the cell function correctly.

Management Team

>Michael Amoroso

Michael Amoroso

President, Chief Executive Officer

Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi. Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

>Jay Bircher

Jay Bircher

Chief Technical Officer

Jay Bircher, Chief Technical Officer, brings more than 28 years of pharmaceutical, biotechnology and medical device experience, knowledge and leadership in the areas of microbiology, quality assurance, quality control, regulatory compliance, validation, sterile manufacturing and operational excellence. Mr. Bircher has lead FDA (CBER and CDER), EMEA and other regulatory body inspections with successful outcomes.

Prior to Abeona, he held quality positions of increasing responsibility with GlaxoSmithKline, Amgen, Tyco Healthcare and most recently Becton, Dickinson and Company (BD), where he was Head of Quality from groundbreaking of a 120,000 ft2-sterile manufacturing facility through an FDA pre-approval inspection (PAI) and eventual launch of several ready-to-administer, prefilled syringe products. Later in his tenure at BD, Mr. Bircher served as Head of Manufacturing where he was responsible for all formulation, fill and packaging operations. He holds a B.S. from Marshall University and is Six Sigma certified.

>Edward Carr

Edward Carr

Chief Accounting Officer, Principal Financial Officer

Ed Carr, Chief Accounting Officer, joined Abeona in 2018, bringing more than 25 years of corporate public accounting experience to the Company. Most recently, he served as Vice President and Assistant Controller at Coty Inc., a publicly listed multinational company. Mr. Carr has significant experience managing various accounting, financial reporting, internal controls, tax and treasury matters. Prior to Coty, he served for more than 10 years as Chief Accounting Officer at Foster Wheeler AG. Mr. Carr, who is a Certified Public Accountant, began his career at Ernst & Young LLP. He holds a B.S. and Master of Professional Accountancy from West Virginia University.

>Jodie Gillon, M.P.H.

Jodie Gillon, M.P.H.

Chief Patient Officer

Jodie Gillon, M.P.H. joined Abeona in 2019, bringing more than 20 years of industry experience in various roles across Development, Medical and Corporate Affairs. Prior to joining Abeona, she cumulatively spent over a decade with Pfizer as the Global Medical Lead for Patient Engagement within the Rare Diseases Business Unit and the Director of Medical Communications within the Chief Medical Office. In these roles, Ms. Gillon facilitated collaborations with patient groups across many therapeutic areas and served as a core member of several cross-functional teams. Prior to Pfizer, she was the Head of Patient Advocacy and Professional Affairs with Achillion Pharmaceuticals. Ms. Gillon also previously served as the Head of the Chief Medical Office of AstraZeneca, which was preceded by additional roles at Novartis and Oridion. She holds a M.P.H. with a dual degree in Health Economics and Epidemiology from Hebrew University in Jerusalem and a BSFS from Georgetown’s School of Foreign Service.

Vishwas Seshadri, Ph.D., M.B.A.

Senior Vice President, Head of Research & Clinical Development

At Celgene (BMS), Dr. Seshadri served in roles of increasing responsibility focused on research & development and commercialization for novel therapies in hematology and oncology, most recently as Executive Director & Worldwide Brand Leader for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. While at Celgene, he led franchise level marketing and the project management office for CAR T commercialization and led teams supporting the successful global launch of Breyanzi®. He also led development project teams for clinical development and regulatory submissions for REVLIMID® (lenalidomide) in lymphoma, strategic go/no-go decisions for Avadomide and IMFINZI® (durvalumab) while implementing program-wide efficiency measures, and managed post-marketing commitments for ISTODAX® (romidepsin). Previously, he was Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories, where he led cell-line development, current Good Manufacturing Practices (cGMP) cell banking, characterization, and cell culture optimization for biosimilars. Dr. Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology and his post-doc in epigenetics at University of Arizona, and earned his M.B.A. in Finance and Healthcare from the Wharton School of the University of Pennsylvania.

>Greg Gin

Greg Gin

Vice President, Investor Relations and Corporate Communications

Greg Gin joined Abeona as Vice President, Investor Relations in May 2020. In this role, he is responsible for all aspects of Abeona’s investor relations program, along with involvement in wider communications programs and supporting the company’s financing activities. Mr. Gin has served as the Head of Investor Relations at four public companies and brings more than 25 years of investor relations, communications, and capital markets experience with small- and mid-cap biotechnology and specialty pharmaceutical companies developing novel treatments for orphan diseases and areas of high unmet medical need. Immediately prior to joining Abeona, Mr. Gin was Head of Investor Relations at Affimed, an immuno-oncology company, where he was responsible for the company’s global investor relations program.

>Kristina Maximenko

Kristina Maximenko

Vice President, Human Resources

Ms. Maximenko has 15 years of human resources experience, having most recently served as the Global HR Director and Head of HR for Advanced Accelerator Applications (AAAP), a Novartis company. Prior to Novartis’ acquisition of AAAP, she was responsible for more than 700 employees operating in a matrix environment within 11 International locations and in more than 20 US states.

Ms. Maximenko has hands-on experience setting up the HR function from the ground up in growing biotechs from pre-clinical to commercialization stage and building out teams in various functional areas including R&D, Medical Affairs, Commercial, Quality & TechOps, and others. She’s got expertise in multiple HR disciplines, including talent acquisition, employee relations, organizational development and compensation.

Ms. Maximenko received a Master of Laws degree in International Law from Far Eastern National University with additional certifications in Human Resources.

>Scott Nogi

Scott Nogi

Vice President, Business Operations

Scott Nogi, Vice President of Business Operations, joined Abeona in 2018 with 20 years of operational and administrative management expertise across a wide range of organizations. In his role, he leads Business Development activities and is responsible for information technology (IT), database management systems (DBMS), and commercial property management. Previously, Mr. Nogi held roles as Vice President of Business Development at Access Pharmaceuticals, Inc., where he worked on partnerships for an oral mucoadhesive product in the cancer space; and Vice President of Operations at SCO Capital Management, a biotech-focused value fund, where he managed all operations, audit, fund administration, IT systems, and human resources. Mr. Nogi also served as Executive Director of Kolot Chayeinu / Voices of Our Lives, a non-profit organization, where he led the business strategy and operations, finances, facilities, and staff. Mr. Nogi earned his MBA in Management and Strategy from the Stern School of Business at New York University and his BFA also from New York University.

>Brendan O’Malley, J.D., Ph.D.

Brendan O’Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

Brendan O’Malley, J.D., Ph.D., joined Abeona in 2019 as Chief IP Counsel, bringing significant technical and legal expertise to the Abeona team.  Prior to joining Abeona, he was a partner at the prominent New York patent litigation firm Fitzpatrick Cella Harper & Scinto, where he started his career as a summer associate in 2006, and then at Venable LLP, which merged with Fitzpatrick in 2018.  While at Fitzpatrick and Venable, Dr. O’Malley litigated a wide variety of biopharmaceutical patent cases in the United States District Courts, at the Federal Circuit, and before the U.S. Patent and Trademark Office, negotiated numerous settlement and license agreements, and provided many patent opinions in connection with M&A due diligence in the biotech space. 

While attending law school at Benjamin N. Cardozo School of Law, Dr. O’Malley served as a judicial intern to Judge William H. Pauley in the U.S. District Court for the Southern District of New York. 

Before law school, he earned a Ph.D. in Molecular Biology & Microbiology from Tufts University School of Medicine, where he studied the role of protein-protein interactions in hepatitis virus assembly, and a B.S. degree magna cum laude from the University of Massachusetts Dartmouth.

>Juan Ruiz, M.D., Ph.D.

Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

Juan Ruiz, Ph.D., joined Abeona as Chief Medical Officer in 2017 and transitioned to Head of European Medical Affairs in October 2018, bringing years of experience in clinical drug development including C-level positions at Lykera Biomed and Digna Biotech, where he spent more than 10 years leading teams dedicated to developing gene therapy translational medicine programs. His proven track record demonstrates a start-to-finish scope, from early preclinical and proof of concept studies to manufacturing, regulatory IND and IMPD submissions, clinical trial design and execution, as well as manufacturing and quality control of the adenoviral vectors. Dr. Ruiz has been instrumental in achieving multiple Orphan Product Designations, has led teams for successful Scientific Advice and Protocol Assistance meetings with the FDA and EMA, and has helped design Patient Reported Outcomes (PRO) in the U.S. to assess skin outcome measures in patients with systemic sclerosis for use as primary endpoints in late-stage clinical trials.

He is the author of more than 40 peer-reviewed journal articles and book chapters and is an inventor on multiple issued patents. Dr. Ruiz earned his Ph.D. in molecular biology from the University of Navarra. He was a post-doctoral fellow at the University of Connecticut and earned his MBA from the IESE Business School at the University of Navarra.

Scientific Leaders

>Brian Kevany, Ph.D.

Brian Kevany, Ph.D.

Director, Product Development

Brian Kevany, Ph.D., joined Abeona at the beginning of 2018 as a scientist in the product development department bringing a significant background in molecular biology and biochemistry to Abeona. Prior to joining Abeona, he managed a small biotechnology startup company which utilized next-generation sequencing for high throughput genotyping in both the medical and agricultural spaces. A postdoctoral research position at the University of Wisconsin-Madison, working on developing new first-line antibiotics to treat drug-resistant tuberculosis, and a Fellowship at Case Western Reserve University, studying a wide range of vision research topics, resulted in an exemplary publication record in a wide range of peer-reviewed journals. His research at Case Western, under the mentorship of Dr. Krzysztof Palczewski, involved studying both the biochemical basis of retinal development as well as the pathophysiology of animal models of blinding diseases.

Prior to his postdoctoral research, he earned a Ph.D. in Molecular and Cellular Biology from the University of Florida, where he studied the role of a hormone receptor family during plant development and a B.S. degree with honors from Michigan State University. 

>Phillip B. Maples, Ph.D.

Phillip B. Maples, Ph.D.

Vice President, Process Development

Dr. Maples has more than 35 years’ experience in international biotechnology, focused on cell and gene therapies, including twelve years at Baxter Healthcare prior to embarking on several business initiatives, exploring clinical and commercial applications of pioneering cell and gene therapies for inherited diseases and cancers. He has worn “many hats” in his career, providing leadership in product development, manufacturing, quality assurance, technical marketing support, regulatory and clinical affairs, but his central focus has been product/process development.

Dr. Maples has teamed to design, construct and or operate more than ten cell and gene therapy processing centers (ex. NIH), gene/cell therapy clinics and GMP manufacturing facilities for biologics. He has held 2 CRADAs with NIH. He has provided professional guidance to universities, private foundations, government bodies, professional societies, public and private companies. Dr. Maples has been on the editorial board of BioProcessing Journal for eighteen years. He has 47 publications, over 170 abstracts and presentations and 17 issued US patents.

>Linas Padegimas, Ph.D.

Linas Padegimas, Ph.D.

Senior Director, Product Development

Linas Padegimas, Ph. D. has 20 years of experience in gene therapy working in the BioTech Industry and 11 years of experience in the academic research labs. He joined Abeona Therapeutics in August 2015 and as Senior Director of Product Development continues leading a team of scientists developing new AAV virus capsids and AAV based gene therapy pre-clinical programs for the list of genetic disorders. From 2005 to 2015 Linas Padegimas lead research of developing gene therapy remedies based on pegylated polylysine compacted DNA technology for cystic fibrosis, Parkinson disease and several ocular inherited diseases at Copernicus Therapeutics Inc. Prior this he was working at Athersys Therapeutics Inc., for various therapy developing projects including gene therapy for Hurler’s disease based on human mini-chromosome synthesis. He has deep expertise in advanced molecular biology techniques for mammalian and plant systems, including extensive experience with: gene therapy vector design and testing, engineering trap-vectors for gene activation or knock-out, creating human synthetic micro-chromosomes and BAC vectors, engineering cDNA and reporter gene expression constructs, mammalian cell manipulations, nuclear injection, microscopy, RTqPCR, expression profiling and other PCR based techniques. Linas Padegimas graduated from Vilnius University, Lithuania (MS in Biochemistry) and earned his PhD in Chemistry with emphasis in molecular biology at Engelhardt Institute of Molecular Biology, Academy of Sciences of Russia.

Board of Directors

Steven H. Rouhandeh
Chairman of the Board

Mr. Rouhandeh has served as a Director of Abeona’s board since the Company’s public debut in 2015, and previously served as Executive Chairman of the Board of Directors from January 2015 to April 2020. He has been Chief Investment Officer of SCO Capital Partners, a group of New York based life sciences funds since 1997. Mr. Rouhandeh possesses a diverse background in financial services that includes experience in asset management, corporate finance, investment banking and law. He has been active throughout recent years as an executive in venture capital and as a founder of several companies in the biotech field. His experience also includes positions as Managing Director of a private equity group at Metzler Bank, a private European investment firm and Vice President, Investment Banking at Deutsche Bank. Mr. Rouhandeh was also a corporate attorney at New York City-based Cravath, Swaine & Moore. Mr. Rouhandeh holds a J.D., from Harvard Law School, Harvard University and B.A. Political Science, from Southern Illinois University.

Michael Amoroso
President, Chief Executive Officer

Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi. Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

Christine Silverstein

Christine Silverstein brings over 15 years of experience in corporate finance and capital markets strategy. Christine serves as Chief Financial Officer at Excision Biotherapeutics, a CRISPR gene-editing company for viral infectious dieseases. Prior to her current role, she was the Chief Financial Officer of Emendo Biotherapeutics, a gene editing company (acquired by Anges Inc, a gene-based medicines company in December 2020). Silverstein formerly served as Chief Financial Officer and Principal Financial Offer for Abeona. She has held various executive roles within the biotechnology industry including Head of Investor Relations at Relmada Therapeutics, Inc., Vice President of Corporate Development at PlasmaTech Biopharmaceuticals, and Managing Director at SCO Financial Group, a life sciences fund. Earlier in her career, she held senior positions at leading New York corporate and capital market advisory firms. Silverstein began her career in financial services as an investment advisor at Royal Alliance Associates. A member of the National Investor Relations Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business at St. John's University and has earned various accreditations from the Financial Industry Regulatory Agency.

Todd Wider, M.D.

Todd Wider, M.D.became a director in May 2015 and serves as a member of the Audit Committee and Compensation Committee. Dr. Wider is a surgeon and has served as consultant to numerous entities in the biotechnology space. Dr. Wider holds an M.D. from Columbia College of Physicians and a B.A. from Princeton University.

Paul Mann

Mr. Mann has over 20 years of experience in the financial and biotechnology industries. Most recently, he served as CFO at PolarityTE, Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that, Mr. Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Procter and Gamble and is named as an inventor on patents for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering.

Faith L. Charles

Ms. Charles is a corporate transactions and securities partner at Thompson Hine with 30 years of legal experience. She leads Thompson Hine’s Life Sciences practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the industry as an astute business advisor, providing valuable insights into capital markets, corporate governance and strategic development.

Ms. Charles serves on the Board of Directors of Entera Bio (Nasdaq:ENTX) as a member of the Audit Committee and Chair of the Compensation Committee. She also serves on the Board of Directors of several private life science companies. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She currently serves on the national board of Women in Bio. Ms. Charles is also a member of the board of Gilda's Club New York City. She has been recognized as a Life Sciences Star by Euromoney’s LMG Life Sciences, has been named a BTI Client Service All-Star, and was named by Crain’s New York Business to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business.

Mark Alvino

Mr. Alvino has provided leadership and experience in the areas of financial management and business strategy as a member of the Board of Directors of multiple life sciences companies, including PainQx, a company with a patented method for objective, quantitative assessment of chronic pain, and previously serving on Abeona’s Board of Directors. He has more than 25 years of experience in the pharmaceutical and biotechnology industries through a range of disciplines including healthcare investment banking, communications, business consulting, market research and health and medical marketing communications. In his role at Hudson Square Capital, Mr. Alvino provides strategic advisory to emerging growth and turnaround biotechnology and medical technology companies. Mr. Alvino is also Founder and Chief Executive Officer of Bridge Back Foundation, focused on addressing the broad underlying issues behind the deadly opioid crisis in America. Previously, he led the Life Sciences team at broker dealer Bradley Woods & Co. Ltd. and served as Managing Director at Griffin Securities and at SCO Financial Group, LLC. Earlier in his career, he spent several years working with Wall Street brokerages including Ladenburg, Thalmann & Co. and Martin Simpson & Co. Mr. Alvino received a B.B.A in Economics and Public Policy from the George Washington University.

Leila Alland, M.D.

Dr. Alland, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Dr. Alland is currently Chief Medical Officer of PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. Previously, Dr. Alland served as Chief Medical Officer at Affimed, and prior to that she held the same position at Tarveda Therapeutics. Dr. Alland also held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late-stage development and contributed to multiple successful drug approvals.

Dr. Alland obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center. Earlier in her career, Dr. Alland served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders. Since 2020, Dr. Alland has served on the Board of Directors of Cytovia Therapeutics, Inc., an immuno-oncology company developing engineered cellular and antibody therapies to treat cancer. Dr. Alland is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a scientific reviewer for the Cancer Prevention and Research Institute of Texas.

Donald Wuchterl

Mr. Wuchterl brings over 29 years of experience in the life sciences industry, with senior roles in operations and Chemistry, Manufacturing, and Controls (CMC). He has significant experience building and leading current Good Manufacturing Practices (cGMP) manufacturing organizations and facilities. Mr. Wuchterl currently serves as Senior Vice President and Chief Manufacturing Officer at T-knife Therapeutics, a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients and their families. Previously, he served as Senior Vice President, Technical Operations & Quality at Audentes Therapeutics (an Astellas Company), a gene therapy company focused on developing and commercializing innovative products for patients living with serious, life-threatening rare neuromuscular diseases. Prior to Audentes, Mr. Wuchterl served as Senior Vice President and Chief Operating Officer at Cytovance Biologics, and held positions of increasing responsibility with Dendreon, Shire HGT, Amgen, Biogen Idec and Roche. Mr. Wuchterl has a B.S. in Business Administration from Colorado Technical University and an M.B.A. from Fitchburg State University.

Scientific Advisory Board

Maria Escolar, MS, M.D.

Maria Escolar, MD, MS is Director, Program for the Study of Neurodevelopment in Rare Disorders (NDRD) and Associate Professor, Pediatrics, University of Pittsburgh School of Medicine. The NDRD was established in 2002 because of the need of help children and their families understand the overall impact of rare neurological diseases in child development. Dr. Escolar is a graduate of the Escuela Colombiana de Medicina. She has a master’s of science in human nutrition from Columbia University and completed a residency in general pediatrics and fellowship in child development and behavior at Cornell University Medical Center in 1995. Dr. Escolar is board-certified in neurodevelopmental disabilities. She has 15 years of experience as a practicing clinician and researcher. Dr. Escolar has authored multiple original manuscripts, including two New England Journal of Medicine articles. She is nationally and internationally known for her work in neurodevelopment of children with leukodystrophies and mucopolysaccharidosis. Her research focuses on behavioral and neuroimaging outcome measurements.

Steven Gray, Ph.D.

Steven Gray, PhD is an Associate Professor in the Department of Pediatrics at the University of Texas Southwestern (UTSW). Dr. Gray earned his PhD in molecular biology from Vanderbilt University in 2006, after earning a BS from Auburn University. He performed a postdoctoral fellowship focusing on gene therapy in the laboratory of Jude Samulski at UNC-Chapel Hill. Dr. Gray is the director of the UTSW Viral Vector Facility and maintains affiliations with the Department of Molecular Biology, the Department of Neurology and Neurotherapeutics, the Eugene McDermott Center for Human Growth and Development, and the Hamon Center for Regenerative Science and Medicine at UTSW.

Dr. Gray's core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system. As AAV-based platform gene transfer technologies have been developed to achieve global, efficient, and in some cases cell-type specific CNS gene delivery, his research focus has also included preclinical studies to apply these reagents toward the development of treatments for neurological diseases. Currently these include preclinical studies for Rett Syndrome, Giant Axonal Neuropathy (GAN), Tay-Sachs, Sandhoff, Krabbe, AGU, Charcot-Marie-Tooth, Batten, and Austin diseases, and have expanded into human clinical studies to test a gene therapy approach for GAN.

Erika Augustine, M.D.

Erika F. Augustine, MD is a Senior Instructor of Neurology and Pediatrics at the University of Rochester Medical Center. She completed undergraduate studies at Harvard College and received her M.D. degree from the University of Rochester. Dr. Augustine completed Pediatrics and Child Neurology residency training at Children’s Hospital Boston in 2008, followed by fellowship training in Pediatric Movement Disorders and Experimental Therapeutics in 2010 at the University of Rochester. Dr. Augustine’s research interests include methodology of clinical research and experimental therapeutics in rare pediatric neurological disorders. Current work focuses on therapeutics in Juvenile Neuronal Ceroid Lipofuscinosis and on the epidemiology of Tourette Syndrome in minorities. She currently serves as Assistant Program Director for the NINDS-funded Experimental Therapeutics training program at the University of Rochester. She is also a member of the NIH Taskforce on Childhood Motor Disorders and is a consultant to the FDA Neurological Devices Panel.

Jonathan Mink, M.D., Ph.D.

Jonathan Mink, MD, PhD, is a Pediatric Neurologist who specializes in movement disorders starting in childhood. He was attracted to pediatric neurology when he was a medical student and realized that he had an intellectual interest in the brain but enjoyed the challenges and rewards of caring for children. As a movement disorders specialist, he cares for children with a variety of conditions that impair voluntary movements, cause involuntary movements, or both. Such conditions include dystonia, chorea, tics, myoclonus, tremor, stereotypies, parkinsonism, and combinations of these such as may occur in conditions like cerebral palsy. In addition to movement disorders, neurodegenerative diseases are also a focus of his clinical practice.

His research has been focused on understanding brain mechanisms involved in the control of movement or where disorders cause involuntary movements. The research involves neurophysiology, direct measurement of movement abnormalities, rating scales, and longitudinal assessments over the course of development and disease. More recently, his work is included clinical trials and studies of factors that impact the function of children with movement disorders. In addition to his clinical practice and research, he directs the Child Neurology residency at the University of Rochester. Dr. Mink serves on a number of advisory boards including the Tourette Syndrome Association, the Dystonia Medical Research Foundation, the Batten Disease Support and Research Association, the NINDS Board of Scientific Counselors, and the Pediatric Advisory Committee of the FDA. He is also an Associate Editor of Neurology.

John Cooper, Ph.D.

Updating bio coming soon.